Dr. Mohamed El Gharabawi

Dr. Mohamed El Gharabawi is a senior medical oncologist at As-Salam International Hospital in Cairo — one of Egypt's leading private hospital groups serving both Egyptian and international patients across the Middle East and North Africa. With 25 years of oncology practice, Dr. El Gharabawi brings extensive experience in diagnosing and treating the full spectrum of solid tumors and hematological malignancies.

Dr. El Gharabawi trained at Cairo University's Faculty of Medicine — the most prestigious medical school in Egypt — and completed advanced oncology training in France, gaining exposure to European standards of cancer care. He returned to Egypt where he has built a distinguished career managing complex oncology cases in a multidisciplinary setting.

His clinical philosophy centers on personalized oncology — tailoring systemic therapy decisions to each patient's tumor biology, molecular profile, and performance status. He is known among colleagues for his thorough approach to treatment planning and for his ability to communicate complex oncological information to patients in compassionate, clear language in both Arabic and English.

As-Salam International Hospital provides Dr. El Gharabawi access to modern oncology infrastructure including PET-CT, molecular diagnostics, and a multidisciplinary tumor board that coordinates surgical, radiation, and medical oncology management.

Dr. El Gharabawi obtained his MD from Cairo University's Faculty of Medicine, one of the oldest and most respected medical institutions in the Arab world. He completed his oncology residency and specialty training in Egypt, earning a PhD in Oncology through Cairo University's postgraduate program, with research focused on medical oncology outcomes in Egyptian cancer patients.

He subsequently completed a Fellowship in Medical Oncology in France, where he trained at a major university cancer center, developing expertise in targeted therapy protocols, clinical trial participation, and the application of molecular profiling to treatment selection. He is a member of both the Egyptian Society of Medical Oncology and the European Society for Medical Oncology (ESMO), maintaining active engagement with international oncology standards and guidelines.

Dr. El Gharabawi's oncology practice covers the major solid tumor types most prevalent in Egypt and the wider MENA region. In breast cancer, he manages hormone receptor-positive, HER2-positive, and triple-negative subtypes with evidence-based regimens including CDK4/6 inhibitors, trastuzumab, and PARP inhibitors where indicated. For colorectal cancer, he prescribes FOLFOX and FOLFIRI regimens with targeted agents including bevacizumab and anti-EGFR therapies for RAS wild-type disease.

In lung cancer management, he applies EGFR, ALK, and PD-L1 testing to guide targeted therapy and immunotherapy. He has significant experience in gynecological oncology, particularly ovarian cancer, and manages lymphoma with CHOP-based regimens. Palliative oncology and supportive care are integral to his practice, with particular attention to pain management and quality of life optimization for advanced-stage patients.

As-Salam International Hospital is a well-established destination for medical tourism from the Gulf states, North Africa, and sub-Saharan Africa. Dr. El Gharabawi consults in Arabic, English, and French, making him accessible to a broad range of international oncology patients seeking second opinions or active treatment. The hospital maintains an international patient department that assists with visa documentation, airport transfers, accommodation coordination, and Arabic-English medical interpretation.

Dr. El Gharabawi offers video consultations for oncology second opinions, allowing international patients to review pathology reports, imaging, and treatment plans remotely before committing to travel for treatment. Egypt offers significantly lower costs for chemotherapy and targeted therapy compared to Western European or Gulf country hospitals.

Dr. El Gharabawi is recognized within Egypt's oncology community for his 25 years of clinical contribution and his role in advancing evidence-based cancer care standards at As-Salam International Hospital. He is an active member of the Egyptian Cancer Society and the Egyptian Society of Medical Oncology, participating in national cancer conferences and continuing medical education activities. His ESMO membership reflects his commitment to aligning Egyptian oncology practice with current European evidence-based standards. He regularly participates in ESMO educational programs and tumor board activities.